Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the management of veno-occlusive disease (VOD) in patients treated with hematopoietic stem cell transplantation (HSCT). Prof. Mohty highlights the approval of the antithrombotic agent defibrotide and the importance of early diagnosis of VOD, which is being made possible with the new EBMT criteria. Evidence suggests VOD is more common and severe in patients treated with post-transplant cyclophosphamide (PTCy). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
